Last reviewed · How we verify
NCT06553976: SP-CERN
Spastic Paraplegia - Centers of Excellence Research Network
trial in Hereditary Spastic Paraplegia in 100 participants. Currently enrolling.
4 June 2026
Quick facts
| Lead sponsor | Boston Children's Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 4 June 2024 |
| Primary completion | 4 June 2026 |
| Estimated completion | 4 June 2027 |
| Sites | 11 locations across United States |
Conditions studied
- Hereditary Spastic Paraplegia — all drugs for Hereditary Spastic Paraplegia →
- Primary Lateral Sclerosis — all drugs for Primary Lateral Sclerosis →
- SPG4 — all drugs for SPG4 →
- SPG5A — all drugs for SPG5A →
Sponsor
Boston Children's Hospital
Who can join
Eligibility, any sex, with Hereditary Spastic Paraplegia or Primary Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06553976
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hereditary Spastic Paraplegia
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07417943 — Neuromodulation to Enhance Motor Function in HSP · NA · recruiting
- NCT06936163 — A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP · recruiting
- NCT06844734 — A Prospective Cohort Study of ITB Treatment for HSP · recruiting
- NCT06478238 — Calcium Folinate Treatment of Spastic Paraplegia 56 · EARLY_PHASE1 · recruiting
Other Boston Children's Hospital trials
Trials by the same sponsor.
- NCT06804382 — Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · NA · not yet recruiting
- NCT05113394 — Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy · Phase 2 · withdrawn
- NCT06434220 — Effect of Predictive Model on ED Physician Assessments of Patient Disposition · NA · not yet recruiting
- NCT07476430 — Readiness Outcomes Affecting Return to Sport 3.0 · NA · not yet recruiting
- NCT06706336 — Radon Asthma Intervention Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06553976 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Children's Hospital
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06553976.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing